Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that Dr. Krassimir Mitchev, PhD, will take over the role as Chief Medical Officer (CMO) from December 1, as Jens Kristensen, PhD, has decided to step down for personal reasons. Dr Kristensen will remain a key member of the medical team of the company.
Dr Kristensen joined Calliditas in 2016 and has been instrumental in the design of the ongoing Phase 3 study (NefIgArd) and the overall clinical development of Calliditas’ leading compound Nefecon.
“I want to thank Jens for the fantastic job he has done for Calliditas as a CMO and member of the leadership team. I am happy that he will continue to dedicate a significant amount of time supporting our development program and KOL network as a key member of the medical team”, said Calliditas’ CEO Renée Aguiar-Lucander.
Dr. Krassimir Mitchev, who is currently Head of Medical Affairs at Calliditas will become acting CMO. Dr. Mitchev is an MD and PhD certified in internal and pulmonary medicine with broad and extensive academic and pharmaceutical industry career experience, including at GSK and UCB. His previous position was Medical Head for Hemophilia at SOBI where he was responsible for driving the development and execution of the full scale global clinical and medical strategy as well as global clinical and medical activities for the TA Hemophilia. He joined Calliditas in March 2019.
“I am excited to work with Krassimir to further develop the existing medical platform and network to ensure the continued success of Nefecon and other pipeline development activities”, said Calliditas’ CEO Renée Aguiar-Lucander.
The information was released for public disclosure, through the agency of the contact person set out below, on November 14, 2019, at 13.45 CET.
For further information, please contact:
Mikael Widell, Head of Communications
Telephone: +46 703 11 99 60
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the Company can partially or completely participate in the commercialization efforts. The Company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas Therapeutics is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the US. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit www.calliditas.com for further information.